Clinic Software← All companies
TECLens
The Future of Vision Correction
health AI/medtech diagnostics and devices for ophthalmology
StageSeries A
Raised$19.9 million (Source) or $10.66 million (Source)
Founded2013
Employees11
LocationStamford, CT
Business modelB2B2C / device with potential service model (in-office treatment)
About
TECLens is a clinical-stage ophthalmic medical device company, pioneering non-invasive personalized corneal cross-linking technology (qCXL™) for vision correction. Our innovative CXLens® system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control. qCXL is designed to be a comfortable, safe, and effective alternative to traditional refractive surgeries. TECLens’ breakthrough technology aims to set a new standard in precision, accessibility, and patient experience—redefining vision correction with innovation that improves quality of life. Caution – Investigational device. Limited by Federal (or United States) law to investigational use.
Product
- Value proposition
- A non-invasive, in-office vision correction technology using qCXL™ and the CXLens® device to strengthen and reshape the cornea for refractive errors and presbyopia, with future expansion to other eye conditions.
- Target customers
- ophthalmology clinics, eye care providers, hospitals offering refractive and corneal treatments
Founders
- David E. Acker — Co-Founder
- Patrick Lopath — Co-Founder & COO
Categories
Products
qCXL™ technologyCXLens® device
Key features
quantitative corneal cross-linking (qCXL)real-time ultrasound monitoringtargeted UV light guidancepersonalized precision planningnon-invasive in-office procedurepotential future applications for additional refractive conditions
Technologies
qCXL™CXLens® devicereal-time ultrasoundUV light-based corneal reshapingpersonalized planning
Target conditions
myopiapresbyopiakeratoconushyperopiamyopia progression in childrenlow-order myopia in adults
Care settings
in-office clinical settingophthalmology cliniceye care practice
Partnerships
Launch Alaska/Launch Lab Partners (as per external link)potential collaborations with ophthalmology practices
Investors
Johnson & Johnson Innovation – JJDC Inc.Yonjin CapitalRimonci CapitalSunmed Capital
News
- First Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction Technology · 2026-02-24T13:00:00.000Z
- TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology · 2025-02-11T00:00:00.000Z
- TECLens: Funding, Team & Investors | Startup Intros · 2026-04-16T00:00:00.000Z
- First Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction Technology - BioSpace · 2026-02-25T03:42:43.000Z
- Study Underway for TECLens' Non-Invasive Vision Correction Technology | Medical Product Outsourcing · 2026-04-20T00:00:00.000Z
- TECLens conducts first clinical trial for non-surgical vision correction technology | HealthCare Middle East & Africa - No.1 Health & Pharma Manufacturing Industry Publication · 2026-03-05T08:14:09.000Z
